News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Sanyou AI-STAL 2.0 Reduces Antibody Discovery Time from Months to 14 Days in Drug Development Breakthrough
Sanyou's AI-STAL 2.0 platform revolutionizes drug discovery by reducing antibody development timelines from months to just 14 days, transforming pharmaceutical R&D.
Gene Expression Analysis Market Reaches $5.93 Billion by 2031, Driving Drug Discovery Innovation
Gene expression analysis market projected to grow from $4.23B in 2026 to $5.93B by 2031 at 7.0% CAGR, led by drug discovery applications.
Perceptive Discovery Partners with MH3D to Launch α-Sight™ Alpha Radiopharmaceutical Imaging Platform
Perceptive Discovery announces strategic partnership with MH3D and launches α-Sight™ preclinical imaging platform for alpha-emitting radiopharmaceuticals in oncology.
P&G Health Launches First APAC Pharmacist Guidelines for Peripheral Neuropathy Management
P&G Health and APAC experts release region's first community pharmacist guidelines for peripheral neuropathy, affecting 1 in 2 diabetics and 1 in 10 adults.
Australia's TGA Updates Assessed Listed Medicines Framework for Enhanced Pre-Market Evaluation
Australia's TGA enhances assessed listed medicines regulations, allowing intermediate health claims with pre-market efficacy evaluation for low-risk ingredients.
Corcept Therapeutics Faces FDA Rejection of Relacorilant for Cushing's Syndrome, Investor Lawsuit Filed
Corcept Therapeutics received FDA Complete Response Letter rejecting relacorilant for Cushing's syndrome due to insufficient evidence, sparking investor lawsuit.
Florida Cancer Specialists & Research Institute Advances Medically Integrated Oncology Care Model
Florida Cancer Specialists & Research Institute showcases leadership in medically integrated oncology care, improving patient outcomes through innovative treatment models.
Phantom Neuro Receives Approval for First Human Trial of Phantom X Neural Interface System
Phantom Neuro gets approval for first-in-human trial of Phantom X neural interface system in Australia, marking major milestone for prosthetic control technology.
Phrontline Biopharma's TJ106 Shows Promise Against HER2-Low and Drug-Resistant Cancers in Preclinical Studies
Phrontline Biopharma presents preclinical data for TJ106, a biparatopic HER2 ADC showing activity in HER2-low and resistant tumors at AACR 2026.
XellSmart Advances XS411 Parkinson's Cell Therapy to Phase II Trial After Positive Phase I Results
XellSmart launches multicenter Phase II trial for XS411, an iPSC-derived dopaminergic cell therapy for Parkinson's disease following encouraging Phase I data.
Peer AI Launches Advanced Regulatory Platform with Predictive Intelligence for Life Sciences Submissions
Peer AI expands its agentic AI platform for life sciences with real-time visibility and predictive regulatory query capabilities to streamline drug submissions.
WuXi Biologics Achieves ISO 13485 Certification for Drug-Device Combination Products Manufacturing
WuXi Biologics becomes first in China to achieve ISO 13485:2016 certification with zero non-conformities for drug-device combination product development.
Atelerix Partners with JH Health to Expand Non-Cryogenic Cell Preservation Technology in Middle East
Atelerix forms strategic partnership with JH Health Ltd to bring revolutionary hydrogel cell preservation technology to Saudi Arabia and Middle East markets.
Chitosan Market Surges 14.3% CAGR as KitoZyme, Primex Lead $7.6B Pharmaceutical Biopolymer Boom by 2036
Global chitosan market projected to reach $7.61 billion by 2036 with 14.3% CAGR, driven by pharmaceutical, cosmetic, and nutraceutical applications.
Telix Pharmaceuticals Doses First Patient in Phase 3 Trial of TLX101-Tx for Recurrent Glioblastoma
Telix begins Phase 3 IPAX-BrIGHT trial of TLX101-Tx, marking the first radiopharmaceutical therapy to reach Phase 3 for recurrent glioblastoma treatment.
NMN 500mg Energy Support Supplement Receives TGA Approval in Australia
Australia's TGA approves NMN 500mg Energy Support supplement (ARTG 525555) containing nicotinamide mononucleotide for metabolic health and energy support.
NMPA Priority Review Granted to AI Diagnostic Tool for Early Cancer Detection
The NMPA has granted priority review to an innovative AI diagnostic tool designed for early cancer detection, promising to revolutionize patient outcomes.
PMDA approves AI-driven platform: What You Need to Know
The PMDA has approved a groundbreaking AI-driven platform, revolutionizing drug development and safety protocols in the pharmaceutical industry.
NMPA Data Integrity: What Pharmaceutical Manufacturers Must Know
Understanding NMPA data integrity is crucial for pharmaceutical manufacturers to ensure compliance and maintain trust in drug safety and efficacy.
AI-Powered Clinical Trial Matching: Accelerating Drug Development in China
AI-driven clinical trial matching is revolutionizing drug development in China, streamlining processes for new therapies and improving patient recruitment.